XML 40 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
 3 Months Ended 9 Months Ended
Jan. 31, 2014
Jan. 31, 2013
Jan. 31, 2014
Jan. 31, 2013
Operating revenue:        
Personalized oncology solutions $ 590 $ 473 $ 1,834 $ 1,850
Translational oncology solutions 3,100 2,444 7,258 4,631
Total operating revenue 3,690 2,917 9,092 6,481
Costs and operating expenses:        
Cost of personalized oncology solutions 614 676 2,139 2,030
Cost of translational oncology solutions 1,008 566 2,585 1,740
Research and development 535 592 1,614 1,415
Sales and marketing 821 658 2,160 2,047
General and administrative 2,120 1,145 4,476 3,484
Total costs and operating expenses 5,098 3,637 12,974 10,716
Loss from operations (1,408) (720) (3,882) (4,235)
Other income (expense):        
Change in fair value of warrant liability 846 (255) (1,202) (21)
Other (expense) (7) (10) (37) (22)
Total other income (expense) 839 (265) (1,239) (43)
Loss before provision for income taxes (569) (985) (5,121) (4,278)
Provision for income taxes 5 5 13 6
Net loss $ (574) $ (990) $ (5,134) $ (4,284)
Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share) $ (0.01) $ (0.02) $ (0.08) $ (0.09)
Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares) 66,867,114 47,737,000 66,860,792 47,294,000